Illumina Hopes to Target $3B Molecular Dx Space with BeadXpress Tests

According to Chief Financial Officer Christian Henry, the recent US Food and Drug Administration clearance of BeadXpress allows Illumina to get to a "whole new class of customers with an FDA-approved instrument," and gives the company a platform to attack rivals in the molecular diagnostics space, such as Luminex.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.